The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LYTGOBI Taiho Pharma Oceania Pty Ltd
Product name
LYTGOBI
Sponsor
Accepted date
Apr-2024
Active ingredients
futibatinib
Proposed indication
For the treatment of metastatic cholangiocarcinoma (CCA).
Application type
A (new medicine)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.